Development of novel platforms for cancer immunotherapy

IVTLab is focused on developing novel platforms for cancer immunotherapy using viruses and cells as starting building blocks.

 

IVTLab started in 2012 and since then it has produced more than 6 patents, tens of publications (see dedicated section) and has raised more than 4 million euros for research.

One of our patent PeptiCRAD constitutes the core business of a spin-off company that together with the University of Helsinki we have setup. The company name is VALO Therapeutics and the primary mission is to bring PetoCRAD technology to the patients.   

 
  Immunotherapy is a way to "wake up" our immune system and use it in the battle against the tumor. Tumors, on the other hands, are very evasive and they promote several mechanisms to avoid being seen and attacked by our body. The IVTLab exploits viruses (that are usually very well seen by our immune system) to make our body aware of the tumor.

 

Immunotherapy is a way to "wake up" our immune system and use it in the battle against the tumor. Tumors, on the other hands, are very evasive and they promote several mechanisms to avoid being seen and attacked by our body. The IVTLab exploits viruses (that are usually very well seen by our immune system) to make our body aware of the tumor.

 

Below are the different research line that IVTLab is pursuing

PeptiCrad

PeptiCrad is the technology that we have developed to rapidly absorb on the virus capsid MHC-I and -II tumor-specific peptides to "convert" the anti-viral immunity into anti-timor immunity.

Learn More →

 

EDIS and EPITOME

We have developed two software for the discovery of heteroclitic peptides and neoantigens

Learn more →

Artboard 3.png

PeptiENV

PeptiENV is a technology that we have developed to attach tumor-specific MHC-I and -II restricted peptides on the envelop of enveloped viruses such as Vaccinia and Herpes virus.

Learn More → 

 

Dendritic Cell Therapy

We have several lines of research on dendritic cell therapy and T cell therapy

Learn more →